The COMT Val158Met polymorphism as an associated risk factor for Alzheimer disease and mild cognitive impairment in APOE 4 carriers Export

@article{citeulike:5874092, abstract = {BACKGROUND:The aim of this study is to examine the influence of the catechol-O-methyltranferase (COMT) gene (polymorphism Val158Met) as a risk factor for Alzheimer's disease (AD) and mild cognitive impairment of amnesic type (MCI), and its synergistic effect with the apolipoprotein E gene (APOE). A total of 223 MCI patients, 345 AD and 253 healthy controls were analyzed. Clinical criteria and neuropsychological tests were used to establish diagnostic groups. The DNA Bank of the University of the Basque Country (UPV-EHU) (Spain) determined COMT Val158Met and APOE genotypes using real time polymerase chain reaction (rtPCR) and polymerase chain reaction (PCR), and restriction fragment length polymorphism (RFLPs), respectively. Multinomial logistic regression models were used to determine the risk of AD and MCI.RESULTS:Neither COMT alleles nor genotypes were independent risk factors for AD or MCI. The high activity genotypes (GG and AG) showed a synergistic effect with APOE 4 allele, increasing the risk of AD (OR= 5.96, 95\%CI 2.74-12.94, p<0.001 and OR= 6.71, 95\%CI 3.36-13.41, p<0.001 respectivily). In AD patients this effect was greater in women. In MCI patients such as synergistic effect was only found between AG and APOE 4 allele (OR= 3.21 95\%CI 1.56-6.63, p=0.02) and was greater in men (OR= 5.88 95\%CI 1.69-20.42, p< 0.01).CONCLUSIONS:COMT (Val158Met) polymorphism is not an independent risk factor for AD or MCI, but shows a synergistic effect with APOE 4 allele that proves greater in women with AD.}, author = {Martinez, Manuel F. and Martin, Xabier E. and Alcelay, Luis G. and Flores, Jessica C. and Juan Maria Uterga Valiente and Juanbeltz, Begona I. and Maria Angeles Gomez Beldarrain and Lopez, Josefa M. and Maria Carmen Gonzalez Fernandez and Salazar, Ana M. and Gandarias, Rocio B. and Borda, Sandra I. and Marques, Nuria O. and Amillano, Miryam B. and Zabaleta, Maria C. and de Pancorbo, Marian M.}, citeulike-article-id = {5874092}, citeulike-linkout-0 = {http://dx.doi.org/10.1186/1471-2202-10-125}, citeulike-linkout-1 = {http://view.ncbi.nlm.nih.gov/pubmed/19793392}, citeulike-linkout-2 = {http://www.hubmed.org/display.cgi?uids=19793392}, day = {30}, doi = {10.1186/1471-2202-10-125}, issn = {1471-2202}, journal = {BMC Neuroscience}, keywords = {ad, citations, comt}, month = {September}, number = {1}, pages = {125+}, posted-at = {2009-10-19 09:08:41}, priority = {2}, title = {The COMT Val158Met polymorphism as an associated risk factor for Alzheimer disease and mild cognitive impairment in APOE 4 carriers}, url = {http://dx.doi.org/10.1186/1471-2202-10-125}, volume = {10}, year = {2009} }

TY - JOUR ID - citeulike:5874092 L3 - citeulike-article-id:5874092 N2 - BACKGROUND:The aim of this study is to examine the influence of the catechol-O-methyltranferase (COMT) gene (polymorphism Val158Met) as a risk factor for Alzheimer's disease (AD) and mild cognitive impairment of amnesic type (MCI), and its synergistic effect with the apolipoprotein E gene (APOE). A total of 223 MCI patients, 345 AD and 253 healthy controls were analyzed. Clinical criteria and neuropsychological tests were used to establish diagnostic groups. The DNA Bank of the University of the Basque Country (UPV-EHU) (Spain) determined COMT Val158Met and APOE genotypes using real time polymerase chain reaction (rtPCR) and polymerase chain reaction (PCR), and restriction fragment length polymorphism (RFLPs), respectively. Multinomial logistic regression models were used to determine the risk of AD and MCI.RESULTS:Neither COMT alleles nor genotypes were independent risk factors for AD or MCI. The high activity genotypes (GG and AG) showed a synergistic effect with APOE 4 allele, increasing the risk of AD (OR= 5.96, 95%CI 2.74-12.94, p<0.001 and OR= 6.71, 95%CI 3.36-13.41, p<0.001 respectivily). In AD patients this effect was greater in women. In MCI patients such as synergistic effect was only found between AG and APOE 4 allele (OR= 3.21 95%CI 1.56-6.63, p=0.02) and was greater in men (OR= 5.88 95%CI 1.69-20.42, p< 0.01).CONCLUSIONS:COMT (Val158Met) polymorphism is not an independent risk factor for AD or MCI, but shows a synergistic effect with APOE 4 allele that proves greater in women with AD. IS - 1 JF - BMC Neuroscience SN - 1471-2202 TI - The COMT Val158Met polymorphism as an associated risk factor for Alzheimer disease and mild cognitive impairment in APOE 4 carriers VL - 10 SP - 125 KW - ad KW - citations KW - comt AU - Martinez, Manuel AU - Martin, Xabier AU - Alcelay, Luis AU - Flores, Jessica AU - Juan Maria Uterga Valiente AU - Juanbeltz, Begona AU - Maria Angeles Gomez Beldarrain AU - Lopez, Josefa AU - Maria Carmen Gonzalez Fernandez AU - Salazar, Ana AU - Gandarias, Rocio AU - Borda, Sandra AU - Marques, Nuria AU - Amillano, Miryam AU - Zabaleta, Maria AU - de Pancorbo, Marian PY - 2009/09/30/ UR - http://dx.doi.org/10.1186/1471-2202-10-125 ER -